GOSSAnother day, another courtroom cameo
Gossamer Bio just got slapped with a securities class action, with investors claiming the company and an executive left them in the dark before the Phase 3 PROSERA study fell flat. The lawsuit covers buyers who picked up shares between June 16, 2025 and February 20, 2026 — basically the whole “please tell me this drug works” stretch.
Why investors care
The core issue is the February 23 bombshell: PROSERA missed its primary endpoint, specifically the change from baseline in six-minute-walk distance at week 24. That kind of miss doesn’t just dent a chart — it can vaporize confidence, trigger a legal mess, and keep the stock stuck in penalty box territory.
The legal hangover
Class actions like this are the market’s version of a sequel nobody asked for. They don’t always move the stock as violently as a failed trial, but they can add legal costs, management distraction, and yet another layer of uncertainty to an already bruised biotech story.
Big picture: when a late-stage trial blows up, the science takes the first hit — and the lawyers usually show up right behind it.